Observational studyThe Journal of rheumatology2018
Renal Remission Status and Longterm Renal Survival in Patients with Lupus Nephritis: A Retrospective Cohort Analysis.
Observational study in The Journal of rheumatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed.
- Secukinumab in active lupus nephritis: results from a phase III randomized, placebo-controlled study (SELUNE) and an open-label extension study.Rheumatology (Oxford, England) · 2026Trial
- Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial.Lupus science & medicine · 2023Trial
- Disease modification in lupus nephritis: towards a pathophysiology-based treatment paradigm.Nature reviews. Nephrology · 2026Review
- Clinical presentations, treatments, and outcomes of pediatric lupus nephritis: a prospective cohort study from the Pediatric Nephrology Research Consortium.Pediatric nephrology (Berlin, Germany) · 2026Article
- Methodological considerations regarding confounding and multivariable adjustment in evaluating SGLT2 inhibitors in systemic lupus erythematosus?International urology and nephrology · 2026Article
- Pathogenesis, Treatment Advances, and Renal Outcomes in Childhood-Onset Lupus Nephritis.Clinical pediatrics · 2026Review
- Article
- Does Voclosporin Redefine Lupus Nephritis Treatment? A Tri-Focal View of Efficacy, Safety, and Costs.Current medical science · 2026Review
- Clinical and Biochemical Factors Associated with Delayed Renal Response in Proliferative Lupus Nephritis: A 20-Year Single-Center Multiethnic Cohort Study.Biomedicines · 2026Article
- Measurements of urinary biomarkers at 2 years following a lupus nephritis flare are associated with subsequent renal outcomes.Lupus science & medicine · 2026Article
- 10 tips on performing economic evaluation in kidney disease.Clinical kidney journal · 2026Review
- Early Renal Remission Is Associated with Increased Likelihood of Subsequent Remission in Lupus Nephritis: Single-Centre Observational Study in Australia.International journal of molecular sciences · 2025Observational
- The unique challenges of childhood-onset systemic lupus erythematosus and lupus nephritis patients: a proposed framework for an individualized transitional care plan.Pediatric nephrology (Berlin, Germany) · 2025Review
- Induction therapy for class I/II lupus nephritis with glucocorticoid monotherapy associates with higher relapse and poorer kidney outcomes.Clinical kidney journal · 2025Article
- Disease-Modifying Therapies in Lupus Nephritis: A Narrative Review Evaluating Currently Used Pharmacologic Agents.Rheumatology and therapy · 2025Review
- Research paper efficacy and safety of telitacicept combined with standard therapy for lupus nephritis: a single-center real-world study.Frontiers in immunology · 2025Article
- Renal response status to predict long-term renal survival in patients with lupus nephritis: results from the Toronto Lupus Cohort.Lupus science & medicine · 2024Observational
- CAR T cell therapy for refractory pediatric systemic lupus erythematosus: a new era of hope?Pediatric rheumatology online journal · 2024Review
- Evaluating the cost-effectiveness of voclosporin for the treatment of lupus nephritis in the United States.Journal of managed care & specialty pharmacy · 2024Article
- Effect of Sustained Clinical Remission on the Risk of Lupus Flares and Impaired Kidney Function in Patients With Lupus Nephritis.Kidney international reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveThis observational study was a retrospective analysis of prospectively collected Hopkins Lupus Cohort data to compare longterm renal survival in patients with lupus nephritis (LN) who achieved complete (CR), partial (PR), or no remission following standard-of-care LN induction therapy.
methodsEligible patients with biopsy-proven LN (revised American College of Rheumatology or Systemic Lupus Collaborating Clinics criteria) were identified and categorized into ordinal (CR, PR, or no remission) or binary (response or no response) renal remission categories at 24 months post-diagnosis [modified Aspreva Lupus Management Study (mALMS) and modified Belimumab International Lupus Nephritis Study (mBLISS-LN) criteria]. The primary endpoint was longterm renal survival [without endstage renal disease (ESRD) or death].
resultsIn total, 176 patients met the inclusion criteria. At Month 24 postbiopsy, more patients met mALMS remission criteria (CR = 59.1%, PR = 30.1%) than mBLISS-LN criteria (CR = 40.9%, PR = 16.5%). During subsequent followup, 18 patients developed ESRD or died. Kaplan-Meier plots suggested patients with no remission at Month 24 were more likely than those with PR or CR to develop the outcome using either mALMS (p = 0.0038) and mBLISS-LN (p = 0.0097) criteria for remission. Based on Cox regression models adjusted for key confounders, those in CR according to the mBLISS-LN (HR 0.254, 95% CI 0.082-0.787; p = 0.0176) and mALMS criteria (HR 0.228, 95% CI 0.063-0.828; p = 0.0246) were significantly less likely to experience ESRD/mortality than those not in remission.
conclusionRenal remission status at 24 months following LN diagnosis is a significant predictor of longterm renal survival, and a clinically relevant endpoint.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.